Julian Teare is Professor of Gastroenterology at Imperial College London and Consultant Gastroenterologist at Imperial College Healthcare NHS Trust and the Royal Marsden NHS Trust.
Professor Teare received his undergraduate medical training at The University of London. He has been based at St Mary’s Hospital for over 20 years, taking up a senior registrar position in Gastroenterology and General Medicine in 1993. Over the last 20 years he has held many distinguished positions within St Mary’s and Imperial College Healthcare NHS trust including Clinical Governance Lead for Medicine, Emergency Services Lead and Service Director for Gastroenterology/Hepatology and Chest medicine. He is head of Endoscopy at the Royal Marsden Hospital.
He has a vast range of teaching and assessment responsibilities. He delivers lectures and seminars to both undergraduate and postgraduate students alongside his ongoing education of doctors and allied healthcare professionals within the NHS. He currently provides academic and pastoral supervision to several PhD students.
His own research career started during his doctoral studies on the aetiology of alcoholic liver disease. He has gone on to be highly cited in the Gastroenterology field with nearly 100 publications to his name. His current research interests are diverse including use of a dudoenal-jejunal sleeve liner for the management of Type 2 diabetes which is the basis of substantial research funding with £1.6million from the NIHR/MRC EME programme. He is active in the Hamlyn Centre developing novel endoscope platforms for use in endoscopy and minimal access surgery with two Wellcome Trust translational awards valued at over £5 million. He is also in receipt of BRC funding from a combined Imperial/Royal Marsden award to investigate the role of intestinal microflora in the development of colorectal cancer.
He also provides specialist advice to distinguished bodies including NICE and the Royal College of Physicians.
et al., 2023, The gut microbiota and metabolome are associated with diminished COVID-19 vaccine-induced antibody responses in immunosuppressed inflammatory bowel disease patients, Ebiomedicine, Vol:88, ISSN:2352-3964
et al., 2022, COVID-19 vaccine-induced antibody and T cell responses in immunosuppressed patients with inflammatory bowel disease after the third vaccine dose: a multicentre, prospective, case-control study, The Lancet Gastroenterology & Hepatology, Vol:7, ISSN:2468-1253, Pages:1005-1015
et al., 2022, Infliximab and tofacitinib attenuate neutralizing antibody responses against SARS-CoV-2 ancestral and Omicron variants in IBD patients following 3 doses of COVID-19 vaccine, Gastroenterology, ISSN:0016-5085
et al., 2022, Oral Beclomethasone Dipropionate is an effective treatment for immune checkpoint inhibitor induced colitis, Journal for Immunotherapy of Cancer, Vol:10, ISSN:2051-1426, Pages:1-10
et al., 2022, COVID-19 VACCINATION RESPONSE IN IMMUNOSUPPRESSED PATIENTS WITH IBD IS ASSOCIATED WITH ALTERED GUT MICROBIOTA FUNCTION, BMJ PUBLISHING GROUP, Pages:A36-A36, ISSN:0017-5749